ANN ARBOR, Mich.--(BUSINESS WIRE)--Feb. 21, 2019--
Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage
biopharmaceutical company developing novel treatments for orphan
endocrine diseases, announced today that Julia C. Owens, Ph.D.,
President and Chief Executive Officer, will present at the 8th
Annual SVB Leerink Global Healthcare Conference in New York City on
Thursday, February 28, 2019 at 11:30 a.m. EST.
A live webcast of the presentation will be available on the Investors &
Media section of Millendo’s website at http://investors.millendo.com.
A replay of the webcast will be archived on Millendo’s website for 30
days following the presentation.
About Millendo Therapeutics, Inc.
Millendo Therapeutics is a
late-stage biopharmaceutical company focused on developing novel
treatments for orphan endocrine diseases where current therapies do not
exist or are insufficient. The Company’s objective is to build a leading
endocrine company that creates distinct and transformative treatments
for a wide range of endocrine diseases where there is a significant
unmet medical need. The Company is currently advancing livoletide for
the treatment of Prader-Willi syndrome and nevanimibe for the treatment
of classic congenital adrenal hyperplasia and endogenous Cushing’s
syndrome. For more information, please visit www.millendo.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190221005135/en/
Source: Millendo Therapeutics, Inc.
Millendo Investor Contact:
Millendo Media Contact: